Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0476089 (endometrial cancer)
 11,379 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The distribution of carcinoembryonic antigen (CEA) and ferritin was demonstrated by immunohistochemical method in 95 patients with normal, hyperplastic, and neoplastic endometrium in order to distinguish among these conditions. Fifteen patients with normal endometrium (NE), 28 with hyperplasia (AH), 12 with atypical hyperplasia (AAH), and 40 with endometrial carcinoma (CA) were studied. Paraffin section tissues were subjected to immunostaining according to the avidin-biotin complex method. CEA was found in 33% of NE cases, 46% of AH, 75% of AAH, and 83% of CA (P less than 0.01). Ferritin was not detected in any case of NE; however, it was detected in one case (4%) of AH, in one case (8%) of AAH, and in 88% of CAs (P less than 0.001). Both tumor markers exhibited a heterogeneous staining pattern, and for a given histologic hyperplastic or malignant lesion, corresponded to several phenotypes. There was no significant correlation between clinical stage or tumor grade and CEA or ferritin expression. In conclusion, ferritin seems to be a better biological marker than CEA in distinguishing between hyperplastic and neoplastic endometrial lesions and it is also more reliable than CEA for endometrial malignancy since it was absent in normal and hyperplastic endometria.
 ...
PMID:Expression of carcinoembryonic antigen and ferritin in normal, hyperplastic, and neoplastic endometrium. 186 94

We have reviewed the clinical usefulness of tumor markers in gynecologic malignancy. In cervical squamous cell carcinoma. SCC and CEA showed increase in frequency of elevated cases according to the clinical stages (FIGO), and the frequency was significantly higher in recurrent cases than in patients with no evidence of disease. In endometrial carcinoma, presently, no specific tumor marker has been found. The diagnostic efficiency of CA 125, CA 19-9 and TPA were 25.2, 23.8 and 32.6, respectively. Further investigation must be necessary to establish markers sensitive enough. In primary ovarian malignancy, combination assay might be much more useful than single assay. The most effective combinations were TPA/CA 125/Ferritin in serous cystadenocarcinoma, and CEA/CA 19-9/TPA in mucinous cystadenocarcinoma. In the monitoring of the disease, it seems to be essential to select suitable combination of markers in each case. In addition, recently, multivariate analysis systems, such as CAMPAS (computer-aided multivariate and pattern analysis system), have become available.
 ...
PMID:[Diagnosis: tumor marker]. 221 48

The changes in serum CA125, CA19-9, CEA, Ferritin, TPA, IAP and LDH concentrations were measured in 22 primary cases and 7 recurrent cases of adenocarcinoma of the uterine cervix and endometrial carcinoma in order to examine the clinical usefullness of CA125 and CA19-9 as a tumor marker. Localization of CA125 and CA19-9 was also examined in adenocarcinoma, normal endocervix and endometrium immunohistochemically. 1. Twenty-seven percent of primary cases had increased serum CA125 and CA19-9 which decreased rapidly after operation or chemotherapy, reflecting reduction of the tumor mass. 2. In these cases, CA125 or CA19-9 was localized in carcinoma tissues immunohistochemically. On the other hand, in normal endocervical and endometrial glands, CA125 was localized, but CA19-9 was not. 3. In most recurrent cases, serum CA125 and CA19-9 increased early and markedly, compared with the other markers. 4. The change in serum Ferritin, CEA, TPA, IAP and LDH didn't reflect clinical courses such as operation and chemotherapy. In recurrent cases they increased even more slowly and slightly than CA125 or CA19-9. These results show that CA125 and CA19-9 are useful tumor markers in the management of adenocarcinoma of the uterine cervix and endometrial carcinoma, especially in advanced or recurrent cases.
 ...
PMID:[Serum CA125 and CA19-9 levels in adenocarcinoma of the uterine cervix and endometrial carcinoma]. 323 84

Ferritin levels in extracts of tumor tissue and serum of patients with gynecological malignancies were assayed by immunodiffusion methods using a standard system of testing for ferritin. A high blood-ferritin level (500-1,000 ng/ml) was found in 8 out 21 patients with ovarian cancer, 8 out of 24 patients with endometrial carcinoma. 2 out of 8 cases of mucinous cystadenoma and in 2 out of 4 cases of pyoovarium. It was lower in other malignancies of the female genital tract. There was no correlation between the ferritin level of blood serum and that of tumor tissue extracts. Although blood serum ferritin was found in very few healthy subjects (2.5%), it is suggested that blood-ferritin level test should be carried out in the course of examination of slowly-progressing purulent adnexitis and mass screening for tumors of female genitals.
 ...
PMID:[Ferritin study in tumors of the female genitalia]. 640 1